Drug Interactions Associated with Sodium-Glucose Cotransporter 2 Inhibitors

WANG Xiaonan; FU Ran; MENG Lu; DING Congyang; DONG Zhanjun

doi:10.14009/j.issn.1672-2124.2020.04.031

您当前的位置：

首页 >

文章列表页 >

Drug Interactions Associated with Sodium-Glucose Cotransporter 2 Inhibitors

更新时间：2022-10-08

- Drug Interactions Associated with Sodium-Glucose Cotransporter 2 Inhibitors
- Vol. 20, Issue 4, Pages: 503-507(2020)
- 作者机构：
  
  1. 河北医科大学研究生学院
  2. 河北省人民医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.04.031
  CLC： R969.2
- Published：2020，
扫描看全文
[1]王小楠,付冉,孟璐,丁琮洋,董占军.钠-葡萄糖共转运蛋白2抑制剂相关的药物相互作用[J].中国医院用药评价与分析,2020,20(04):503-507.

WANG Xiaonan, FU Ran, MENG Lu, et al. Drug Interactions Associated with Sodium-Glucose Cotransporter 2 Inhibitors. [J]. 20(4):503-507(2020)
[1]王小楠,付冉,孟璐,丁琮洋,董占军.钠-葡萄糖共转运蛋白2抑制剂相关的药物相互作用[J].中国医院用药评价与分析,2020,20(04):503-507. DOI： 10.14009/j.issn.1672-2124.2020.04.031.

WANG Xiaonan, FU Ran, MENG Lu, et al. Drug Interactions Associated with Sodium-Glucose Cotransporter 2 Inhibitors. [J]. 20(4):503-507(2020) DOI： 10.14009/j.issn.1672-2124.2020.04.031.

摘要

钠-葡萄糖共转运蛋白2（sodium-glucose cotransporter 2

SGLT-2）抑制剂是治疗2型糖尿病的新型口服药物。SGLT-2抑制剂通过降低肾糖阈

增加尿葡萄糖排泄

同时排出部分能量;由于SGLT-2抑制剂的降糖机制依赖于血液和尿液中葡萄糖的浓度差

因此

在血糖较低的时候其效用就大大减弱

从而降低了低血糖发生风险。在降血糖外

SGLT-2抑制剂还有诸多获益

包括降低收缩压、舒张压

改变血液动力学

提高血细胞比容;降低体质量

减少内脏脂肪和皮下脂肪;降低尿酸;对心脏、肾脏还有保护作用。本文就我国批准使用的SGLT-2抑制剂恩格列净、达格列净和卡格列净的药物相互作用进行综述

以期为临床医师和药师合理用药提供参考。

Abstract

Sodium-glucose cotransporter 2（ SGLT-2） inhibitor is a kind of new oral drug for the treatment of type2 diabetes. SGLT-2 inhibitors increase urinary glucose excretion by lowering the renal glucose threshold while expelling some energy. The hypoglycemic mechanism of SGLT-2 inhibitors depends on the difference in glucose concentration in blood and urine

when the blood sugar is lower

its effectiveness is greatly weakened

and the risk of hypoglycemia decreased. In addition to lowering blood sugar

SGLT-2 inhibitors have many benefits

including lowering systolic and diastolic blood pressure

altering hemodynamics

increasing hematocrit

reducing body mass

reducing visceral and subcutaneous fat

reducing uric acid

and protecting the heart and kidney. This paper reviews the drug interactions of the SGLT-2 inhibitors empagliflozin

dapagliflozin and canagliflozin that are approved for use in China

so as to provide reference for rational drug use by clinicians and pharmacists.

关键词

恩格列净达格列净卡格列净相互作用

Keywords

EmpagliflozinDapagliflozinCanagliflozinInteraction

references

查看原文

Views

318

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Dapagliflozin Combined with Liraglutide on Inflammatory Factors, Glucolipid Metabolism and Liver Function in Patients with Type 2 Diabetes Combined with Non-Alcoholic Fatty Liver Disease

Clinical Study of Empagliflozin Combined with Insulin Aspart in the Treatment of Patients with Type 2 Diabetes Poorly Controlled by Insulin Alone

Research on Activities of in vitro Anti-Tuberculosis of Faropenem and Biapenem

Related Author

CHU Yang

WANG Deqin

LYU Zhongmei

ZHAO Guishi

DAI Yuelong

HUANG Zichong

ZHAO Weijie

LIU Jing

Related Institution

Dept.of Nephroendocrinology, Hai’an Hospital Affiliated to Nantong University

Dept.of Pharmacy,Hospital of China People’s Police University

Dept.of Medicine,Hospital of China People’s Police University

Office of Drug Clinical Trial Institutions,Beijing Chest Hospital Affiliated to Capital Medical University

Dept.of Pharmacy,Beijing Chest Hospital Affiliated to Capital Medical University

⁰